M&As this week: Incyte, Aptuit

Incyte has announced it will acquire ARIAD Pharmaceuticals for a sale consideration of $140m, to expand its medical and commercial market in Europe and develop its clinical development and product portfolio.

According to the agreement, Incyte will acquire all shares of ARIAD Pharmaceuticals. ARIAD will be responsible for the commercialisation of Iclusig in the US, allowing it to strengthen its financial position.

Aptuit, a pharmaceutical services company, has acquired Kuecept, a drug development service provider, to expand its formulation capabilities.

The acquisition enables Aptuit to develop and expand its pre-formulation, formulation prototyping and formulation development services.